Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) and Repare Therapeutics (RPTX – Research Report).
Roche Holding AG (RHHVF)
Morgan Stanley analyst Mark Purcell maintained a Hold rating on Roche Holding AG today and set a price target of CHF290.00. The company’s shares closed last Wednesday at $276.30, close to its 52-week low of $264.82.
Purcell has an average return of
According to TipRanks.com, Purcell is ranked #1978 out of 8571 analysts.
Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $327.58, which is a 17.0% upside from current levels. In a report issued on October 11, Jefferies also maintained a Hold rating on the stock with a CHF285.00 price target.
See the top stocks recommended by analysts >>
Repare Therapeutics (RPTX)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Repare Therapeutics today and set a price target of $25.00. The company’s shares closed last Wednesday at $4.86.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Repare Therapeutics with a $21.00 average price target, representing a 314.2% upside. In a report issued on October 13, Stifel Nicolaus also maintained a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RHHVF:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
- Genentech announces results from primary analysis of ALINA study
- Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns
- Roche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
- Monte Rosa Therapeutics announces strategic collaboration with Roche
